Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 24:16:25.
doi: 10.1186/s12883-016-0549-8.

Pain management strategies for neuropathic pain in Fabry disease--a systematic review

Y Schuller  1 , G E Linthorst  2 , C E M Hollak  3 , I N Van Schaik  4 , M Biegstraaten  5
Affiliations

Pain management strategies for neuropathic pain in Fabry disease--a systematic review

Y Schuller et al. BMC Neurol. .

Erratum in

Abstract

Background: Neuropathic pain is one of the key features of (classical) Fabry disease (FD). No randomized clinical trials comparing effectiveness of different pain management strategies have been performed. This review aims to give an overview of existing pain management strategies.

Methods: PubMed and Embase were searched up to September 2014 for relevant articles on treatment of neuropathic pain in FD.

Results: Seven-hundred-thirty-one articles were identified of which 26 were included in the analysis. Studies reported on 55 individuals in total, with group-sizes ranging from 1 to 8. Carbamazepine appeared most beneficial: complete pain relief in 5/25, partial relief in 17/25, and no benefit in 3/25 patients. Phenytoin resulted in complete relief in 1/27, partial relief in 12/27 and no benefit in 6/27 patients. In 8 patients a significant reduction in the frequency of pain attacks was described. Gabapentin caused partial relief in 6/7 and no relief in 1/7 patients. Little evidence was reported for SSNRI's or treatment combinations. Adverse-effects were reported in all treatment strategies.

Conclusions: Only for carbamazepine, phenytoin and gabapentin there is evidence of effectiveness in neuropathic pain due to FD, but comparison of effectiveness between these drugs is lacking. In routine clinical practice adverse-effects may discourage use of carbamazepine and phenytoin in favor of second-generation antiepileptic drugs, but this is currently not supported by clinical evidence. This review suffers greatly from incomplete outcome reports and a predominance of case reports, which emphasizes the need for robust clinical trials and observational cohort studies.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study flow diagram. Numbers of studies screened, assessed for eligibility, and included in the review
See this image and copyright information in PMC

References

    1. Brady RO, et al. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276(21):1163–1167. doi: 10.1056/NEJM196705252762101. - DOI - PubMed
    1. Biegstraaten M, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36. doi: 10.1186/s13023-015-0253-6. - DOI - PMC - PubMed
    1. Ishii S, et al. Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Commun. 1993;197(3):1585–1589. doi: 10.1006/bbrc.1993.2659. - DOI - PubMed
    1. van der Tol L, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1–9. doi: 10.1136/jmedgenet-2013-101857. - DOI - PubMed
    1. Mehta A, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236–242. doi: 10.1111/j.1365-2362.2004.01309.x. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources